# Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

> **NCT03492918** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03492918
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2023-04
- **Final completion:** 2023-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492918, "Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03492918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*